Literature DB >> 7841860

Overview: a comparison of withdrawal symptoms from different drug classes.

R West1, M Gossop.   

Abstract

Whereas early formulations of addictive behaviour placed great emphasis upon withdrawal as a defining feature, current views focus more upon compulsive use as its central characteristic. However, the withdrawal syndrome continues to occupy an important place in the study of the addictions. It is interesting both in its own right and in relation to the development and maintenance of the compulsive use of drugs. Despite the attention devoted to withdrawal phenomena over many years, precise demarcation of the withdrawal symptoms associated with drugs of dependence has proved difficult to achieve. Withdrawal from all drugs of dependence appears to lead to mood disturbances although the extent to which these are due to the pharmacological actions of the drugs or to other physiological or psychological processes is unclear. Sleep disturbance is also common, although again direct links with the pharmacological actions of the withdrawn drug are yet to be established. Withdrawal from alcohol, benzodiazepines and opiates is often associated with somatic symptoms. In the former two cases, these can involve sweating, tremor and occasionally seizures. Perceptual disturbances have also been reported. In the case of opiates, flu-like symptoms are often reported, including muscle aches and gastric disturbances. In the case of nicotine, heightened irritability has been established as a direct pharmacological withdrawal effect. Characterization of stimulant withdrawal is still uncertain. There is little evidence of somatic symptoms but depression may occur as a result of a physiological rebound. There is also uncertainty over what role pharmacological withdrawal symptoms play in maintaining compulsive use.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7841860     DOI: 10.1111/j.1360-0443.1994.tb03747.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  26 in total

1.  Problem drinking and low-dose naltrexone-assisted opioid detoxification.

Authors:  Paolo Mannelli; Kathleen Peindl; Ashwin A Patkar; Li-Tzy Wu; Haresh M Tharwani; David A Gorelick
Journal:  J Stud Alcohol Drugs       Date:  2011-05       Impact factor: 2.582

2.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

3.  Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.

Authors:  Simon Zhornitsky; Emmanuel Stip; Joelle Desfossés; Tania Pampoulova; Elie Rizkallah; Pierre-Paul Rompré; Lahcen Aït Bentaleb; Olivier Lipp; Jean-Pierre Chiasson; Alain Gendron; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2011-05-13       Impact factor: 4.157

Review 4.  Alcohol dependence as a chronic pain disorder.

Authors:  Mark Egli; George F Koob; Scott Edwards
Journal:  Neurosci Biobehav Rev       Date:  2012-09-11       Impact factor: 8.989

Review 5.  The behavioral- and neuro-economic process of temporal discounting: A candidate behavioral marker of addiction.

Authors:  Warren K Bickel; Mikhail N Koffarnus; Lara Moody; A George Wilson
Journal:  Neuropharmacology       Date:  2013-06-24       Impact factor: 5.250

Review 6.  Circuits and functions of the lateral habenula in health and in disease.

Authors:  Hailan Hu; Yihui Cui; Yan Yang
Journal:  Nat Rev Neurosci       Date:  2020-04-08       Impact factor: 34.870

7.  Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF₁ receptor antagonism.

Authors:  Scott Edwards; Leandro F Vendruscolo; Joel E Schlosburg; Kaushik K Misra; Sunmee Wee; Paula E Park; Gery Schulteis; George F Koob
Journal:  Neuropharmacology       Date:  2011-11-23       Impact factor: 5.250

8.  Do client attributes moderate the effectiveness of a group cognitive behavioral therapy for depression in addiction treatment?

Authors:  Sarah B Hunter; Susan M Paddock; Annie Zhou; Katherine E Watkins; Kimberly A Hepner
Journal:  J Behav Health Serv Res       Date:  2013-01       Impact factor: 1.505

9.  Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.

Authors:  Jonathan D Raybuck; George S Portugal; Caryn Lerman; Thomas J Gould
Journal:  Behav Neurosci       Date:  2008-10       Impact factor: 1.912

Review 10.  Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.

Authors:  William P Cheshire; Robert D Fealey
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.